Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Average (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Equity Average for 12 consecutive years, with $614.2 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 19.79% to $614.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $614.2 million through Dec 2025, down 19.79% year-over-year, with the annual reading at $678.5 million for FY2025, 17.02% up from the prior year.
  • Equity Average for Q4 2025 was $614.2 million at Madrigal Pharmaceuticals, down from $660.9 million in the prior quarter.
  • The five-year high for Equity Average was $853.9 million in Q2 2024, with the low at $47.1 million in Q3 2022.
  • Average Equity Average over 5 years is $388.7 million, with a median of $251.5 million recorded in 2021.
  • The sharpest move saw Equity Average crashed 81.37% in 2022, then surged 1199.57% in 2024.
  • Over 5 years, Equity Average stood at $215.5 million in 2021, then crashed by 51.73% to $104.0 million in 2022, then soared by 105.51% to $213.8 million in 2023, then surged by 258.19% to $765.8 million in 2024, then decreased by 19.79% to $614.2 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $614.2 million, $660.9 million, and $703.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.